Albert Qin

Chief Medical Officer
PharmaEssentia Corporation

Graduated in Medicine from the medical department of Shandong Medical University. Ph.D. in Biochemistry and Molecular Pharmacology from Harvard University School of Medicine. Having served as the Chief Medical Officer of PharmaEssentia Corporation from January 2017 to present. Previously served as Medical Director and Head of Clinical Development at ImmunoGen, Chief Scientific Officer and Corporate Officer of SymBio Pharmaceuticals, Chief Medical Officer of China Health Group. Directly involved in and served as the Medical Group Leader during the biologic license application for the Besremi (R) approval in the US. Have approximately over 70 important publications. He is the originator of the theory regarding the cell cycle-based anticancer surveillance system.
 

Speech title & Synopsis

Outstanding Company of the Year

PharmaEssentia Corporation (Taiwan Stock Exchange, TWSE: 6446) is a fully integrated global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to stakeholders.

PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company is committed to the improvement of health and quality of life for patients suffering from these diseases.

 The Company’s world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and is designed and operated to be compliant with all U.S. FDA and EMA requirements.